Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2016 16:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Corp. Reports Second Quarter 2016 Financial Results

Quarterly Revenue Increased 37.3% Year-Over-Year, to $32.0 Million Raptor Raises 2016 Global Net Revenue Guidance to $125-$135 Million Company to Host Conference Call and Webcast Today at...
August 01, 2016 10:05 ET | Source: Vaccinex, Inc.

Vaccinex Receives FDA Fast Track Designation for VX15 Antibody for the Treatment of Huntington’s Disease

ROCHESTER, N.Y., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VX15 as a potential...
July 28, 2016 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Hold Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4, 2016, at 4:30 p.m. EDT

NOVATO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release second quarter 2016 financial results on Thursday, August 4,...
June 07, 2016 16:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Present Data on QUINSAIR™ at European Cystic Fibrosis Conference

NOVATO, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
April 28, 2016 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET

NOVATO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5,...
March 16, 2016 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled Levofloxacin

Granted for Three Distinct Indications: Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis and in Patients with Non-Cystic Fibrosis Bronchiectasis as...
February 29, 2016 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Participate in International Rare Disease Week Through Multiple Patient Advocacy Activities

NOVATO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its support of Rare Disease Week, beginning February 29, 2016, with a series of activities...
January 25, 2016 07:05 ET | Source: Raptor Pharmaceutical Inc

Four New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan Exclusivity

Five Patents for PROCYSBI Now Listed in FDA Orange Book Orphan Drug Exclusivity Extended in Nephropathic Cystinosis Patients 2-6 Years Old NOVATO, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Raptor...
November 16, 2015 07:05 ET | Source: Raptor Pharmaceutical Inc

NIDDK Provides Additional Data From CyNCh Study Evaluating RP103 in Pediatric NASH at AASLD

NOVATO, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced researchers have provided additional results from the CyNCh study of RP103 for the treatment...
October 29, 2015 16:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Hold Third Quarter 2015 Financial Results Conference Call and Webcast on Thursday, November 5, 2015, at 4:30 p.m. ET

NOVATO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2015 financial results on Thursday, November 5,...